Global Markets Direct’s, 'Bacteremia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bacteremia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacteremia. Bacteremia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Bacteremia. - A review of the Bacteremia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bacteremia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Bacteremia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bacteremia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Bacteremia - Pipeline Review, H1 2013 Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Bacteremia Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Bacteremia 7 Bacteremia Therapeutics under Development by Companies 9 Mid Clinical Stage Products 10 Comparative Analysis 10 Early Clinical Stage Products 11 Comparative Analysis 11 Discovery and Pre-Clinical Stage Products 12 Comparative Analysis 12 Bacteremia Therapeutics - Products under Development by Companies 13 Nabriva Therapeutics AG 14 Sinovac Biotech Ltd. 15 Trius Therapeutics, Inc. 16 Max Planck Innovation GmbH 17 Bacteremia - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Drug Profiles 23 BC-3781 - Drug Profile 23 Product Description 23 Mechanism of Action 23 RandD Progress 23 tedizolid phosphate - Drug Profile 24 Product Description 24 Mechanism of Action 24 RandD Progress 24 Pneumococcal Polysaccharides Vaccine - Drug Profile 26 Product Description 26 Mechanism of Action 26 RandD Progress 26 Drugs For Human Septicaemia - Drug Profile 27 Product Description 27 Mechanism of Action 27 RandD Progress 27 MAb Against S aureus - Drug Profile 28 Product Description 28 Mechanism of Action 28 RandD Progress 28 Human Neutrophil Alpha Defensin-1 - Drug Profile 29 Product Description 29 Mechanism of Action 29 RandD Progress 29 Human Neutrophil Alpha Defensin-2 - Drug Profile 30 Product Description 30 Mechanism of Action 30 RandD Progress 30 Human Neutrophil Alpha Defensin-3 - Drug Profile 31 Product Description 31 Mechanism of Action 31 RandD Progress 31 ceftriaxone sodium CR - Drug Profile 32 Product Description 32 Mechanism of Action 32 RandD Progress 32 Bacteremia Therapeutics - Drug Profile Updates 33 Bacteremia Therapeutics - Discontinued Products 39 Bacteremia Therapeutics - Dormant Products 40 Bacteremia - Product Development Milestones 41 Featured News and Press Releases 41 Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate Cubicin At ICAAC 2012 41 Apr 11, 2011: Trius Announces Patent Term Extension For Torezolid Phosphate 41 Apr 04, 2011: Cubist Pharma Settles CUBICIN Patent Litigation With Teva 42 Dec 01, 2010: Cubist Receives FDA Approval For Two-Minute IV Injection Of CUBICIN 42 Jul 13, 2010: Cubist Announces Objectives Met in Phase 2 Safety Study of CUBICIN in Prosthetic Joint Infections 43 May 12, 2010: Markman Hearing in CUBICIN Patent Litigation Rescheduled to June 9, 2010 43 Dec 11, 2009: Trial Date Set for CUBICIN Patent Litigation 44 Jan 05, 2009: Cubist Pharmaceuticals, the Developer of CUBICIN, Announces Submission of 2 INDs Targeting Serious Infections Caused by MDR Gram-negative Pathogens and by Clostridium difficile 44 Oct 21, 2008: CUBICIN Outcomes Registry and Experience (CORE) Marks Milestone 44 Oct 16, 2008: Cubist Pharmaceuticals Q3 2008 Revenues up 41%; Net Income up 39%: Total Revenues $112.4 Million; CUBICIN Net Product Revenues $110.6 Million 44 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 47 Disclaimer 47
List of Tables
Number of Products Under Development for Bacteremia, H1 2013 7 Products under Development for Bacteremia - Comparative Analysis, H1 2013 8 Number of Products under Development by Companies, H1 2013 9 Comparative Analysis by Mid Clinical Stage Development, H1 2013 10 Comparative Analysis by Early Clinical Stage Development, H1 2013 11 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 12 Products under Development by Companies, H1 2013 13 Nabriva Therapeutics AG, H1 2013 14 Sinovac Biotech Ltd., H1 2013 15 Trius Therapeutics, Inc., H1 2013 16 Max Planck Innovation GmbH, H1 2013 17 Assessment by Monotherapy Products, H1 2013 18 Assessment by Stage and Route of Administration, H1 2013 20 Assessment by Stage and Molecule Type, H1 2013 22 Bacteremia Therapeutics - Drug Profile Updates 33 Bacteremia Therapeutics - Discontinued Products 39 Bacteremia Therapeutics - Dormant Products 40
List of Figures
Number of Products under Development for Bacteremia, H1 2013 7 Products under Development for Bacteremia - Comparative Analysis, H1 2013 8 Products under Development by Companies, H1 2013 9 Mid Clinical Stage Products, H1 2013 10 Early Clinical Stage Products, H1 2013 11 Discovery and Pre-Clinical Stage Products, H1 2013 12 Assessment by Monotherapy Products, H1 2013 18 Assessment by Route of Administration, H1 2013 19 Assessment by Stage and Route of Administration, H1 2013 20 Assessment by Molecule Type, H1 2013 21 Assessment by Stage and Molecule Type, H1 2013 22